Tumor cell invasion and metastasis are a complex multistep process that involves the degradation of extracellular matrix proteins by matrix metalloproteinases. Tissue inhibitor of metalloproteinase -1 ( TIMP -1 ) acts as a negative regulator of matrix metalloproteinases and thus prevents tumor cell invasion and metastasis by preserving extracellular matrix integrity. In the present study, we investigated whether increasing serum TIMP -1 levels by gene transfer would decrease experimental pulmonary metastasis of melanoma in C57BL / 6 mice. Female animals bearing B16F10 melanoma pulmonary metastasis were injected intramuscularly twice per week with 100 g of plasmid DNA encoding the human TIMP -1 cDNA ( TIMP -1pDNA ). Substantive levels of serum human TIMP -1 were observed 3 days after single injection and were found for 6 days thereafter. Pulmonary metastasis was significantly reduced in the mice following 4 weeks of TIMP -1 treatment as compared to the controls that were treated with the plasmid DNA vector alone. Further reduction of pulmonary metastasis and increase in survival were realized by intraperitoneal injection of 1000 U of IL -2 twice per week in combination with TIMP -1 treatment. In a parallel in vitro study, a 3 -fold increase in TIMP -1 expression was observed in NIH3T3 cells after IL -2 treatment. Therefore, up -regulation of TIMP -1 expression by IL -2 likely contributed to the additive effect of IL -2 and TIMP -1 in reducing metastatic disease in the animal model. In conclusion, our findings support the potential of TIMP -1 gene therapy for the prevention of metastatic melanoma.
T umor cell invasion and metastasis define malignancy and are major causes of cancer mortality.
1,2 Degradation of the extracellular matrix (ECM ) surrounding cancer cells is an essential step in the process of cancer invasion and metastasis. 3, 4 Matrix metalloproteinases ( MMPs ), also called matrixins, constitute a family of zinc -dependent endopeptidases that are responsible for the degradation of ECM components such as collagens, laminin, fibronectin, and proteoglycans. No less than 23 members of this family have been identified so far. Collectively, MMPs play an important role in ECM homeostasis, mediating such normal physiological processes as embryogenesis, organ morphogenesis, reproduction, angiogenesis, and tissue resorption and remodeling. 5 The proteolytic activities of MMPs are tightly regulated by endogenous inhibitors, -macroglobulins, and tissue inhibitors of metalloproteinases ( TIMPs ). 5 Any disruption of this fine balance can result in serious diseases such as arthritis, periodontal disease, and cancer metastasis. 6 It has been
shown that tumor cells expressing high levels of these enzymes are highly metastatic. 7 -11 TIMPs are the major endogenous regulators of MMP activities in the tissue, and presently comprise four members ( TIMP -1 to TIMP -4 ) with 40-50% sequence identity. 12 -14 All TIMPs inhibit active MMPs with relatively low selectivity, forming tight noncovalent 1:1 complexes. 13 -15 TIMP-1 is a secreted 28.5 -kDa glycoprotein of 184 amino acids. The protein is widely distributed and inhibits the activity of all MMPs. Several studies have demonstrated that TIMP -1 can inhibit tumor cell invasion and metastasis when overexpressed in tumor cells.
3,5 TIMP -1 overexpression has also been found in stromal tissues surrounding the invading tumors such as non-Hodgkin's lymphoma, 16 gliomas, 17 colon, 18 and thyroid carcinomas, 19 suggesting that TIMP-1 overexpression in stroma may play an important role in inhibiting tumor cell invasion. It is, however, not known whether increasing serum TIMP -1 level by gene transfer would result in a decrease in tumor cell invasion and metastasis.
Interleukin-2 (IL -2) has been widely used in the immunotherapy of tumors. 20 In mice, adoptive immunotherapy with lymphokine -activated killer (LAK ) cells and systemic IL -2 causes regression of established solid tumors and disseminated leukemias and lymphomas. 20 Melanoma lung metastasis in mice could be cured by chronic indomethacin and IL -2 treatment. 21 Patients with advanced malignancies have been successfully treated with LAK cells and IL-2 therapy. The most impressive results were achieved in patients with renal cells cancer and melanoma, with response rates ranging between 10% and 30%. 20 To our knowledge, the effect of IL -2 together with TIMP -1 in antitumor metastasis has not been evaluated thus far.
In the present study, we investigated whether increasing serum TIMP-1 levels by gene transfer would lead to a reduction in experimental lung metastasis induced by tailvein injection of B16F10 melanoma cells, which is one of the most aggressive, poorly immunogenic murine tumors. 22 The role of IL -2 in reducing experimental lung metastasis was also studied, both alone and in combination with TIMP-1 gene therapy.
Materials and methods

Animals
Female C57BL /6 mice at 8-10 weeks of age were used as model hosts for the production of experimental pulmonary metastasis. To establish lung metastasis of B16F10 melanoma, mice were injected intravenously ( i.v.) with 2Â10 5 B16F10 cells. On day 30 following tumor cell injection, five to six mice from each group were sacrificed, and the lungs were removed and fixed in Bouin's fixative followed by counting of tumor nodules under a dissecting microscope. The same numbers of mice 5 -7 were processed for survival studies.
Cell lines and cell culture B16F10 is a spontaneously arising melanoma cell line derived from a C57BL / 6 mouse. The line was kindly provided by Dr. IJ Fidler. 22 NIH3T3 mouse cell line was obtained from ATCC ( Rockville, MD ). Cell culture was propagated in either RPMI 1640 ( B16F10 ) or Dulbecco's modified Eagle medium (NIH3T3) containing 10% fetal bovine serum, 2 mM L -glutamine, 100 U /mL penicillin, and 100 g /mL streptomycin at 378C in humidified atmosphere containing 5% CO 2 .
Induction of TIMP -1 expression by cytokines NIH3T3 cells, cultivated in 100-mm 2 culture dishes, were treated either with IL -2 (500 U /mL ), TGF -1 (20 ng /mL ), IL -12 (25 ng /mL ), IL -4 (100 U / mL ), or IFN -(1000 U / mL ) for 24 hours. Total RNA was extracted and TIMP-1 expression was determined by Northern blot analysis as described previously.
19
Plasmids TIMP -1pDNA was constructed by cloning the human TIMP -1 cDNA into pRc /CMV, a eukaryotic expression vector from Invitrogen ( San Diego, CA ), as described previously. 19 pRc /CMV-lacZ, which contains the -galactosidase gene, also obtained from Invitrogen plasmid DNA, was routinely prepared by bacterial fermentation and purified using a standard plasmid isolation kit (QIAGEN, Valencia, CA ). All plasmid preparations were free of detectable RNA and yielded spectrophotometric A 260 /A 280 ratios between 1.80 and 2.0.
In vitro tumor invasion assay
In vitro transfection of NIH3T3 cells with TIMP -1pDNA and control plasmid DNA (pRc /CMV ) was performed as described previously. 19 Tissue culture supernatants were collected 48 hours after transfection. The supernatants were used in an in vitro tumor invasion assay to test whether secreted TIMP -1 from supernatants could inhibit the invasive potential of B16F10 melanoma cells through the basement membrane. 23 Briefly, 3 -m pore size filters in the Transwell insert (Costar, Cambridge, MA ) were coated with 25 L of basement membrane matrigel ( 1 mg / mL ) (Collaborative Research, Bedford, MA ). The Transwell insert was then placed in a Costar 24-well cluster plate. B16F10 cells were labeled with 1 Ci /mL 125 Ideoxyuridine and resuspended in the supernatants collected from cultures transfected with TIMP-1pDNA or pRc / CMV plasmid DNA ( control ). Viable cells, 2.5Â10 5 , were added to the upper compartment of the chamber in a total volume of 0.5 mL. The lower compartment was filled with 0.5 mL of medium. After incubation for 96 hours at 378C in a humidified atmosphere containing 5% CO 2 , B16F10 cells that had migrated to the lower surface of the filters were recovered with trypsin -EDTA and counted in a gamma counter.
Intramuscular ( i.m. ) injections
Fifty micrograms of plasmid DNA in 50 L of saline was injected into the rectus femoris muscle of each hind leg for a total concentration of 100 g of DNA per animal, as described by Horton et al. 24 Determination of serum levels of hTIMP -1 A single i.m. injection of 100 g of TIMP-1pDNA was administered to six C57BL /6 mice. Serum was collected every 2 -3 days for 9 days postinjection and analyzed using a human TIMP-1 ELISA kit (Oncogene Research Products, Cambridge, MA ).
Statistical analyses
The significant difference in the number of lung metastatic nodules between two groups of animals was analyzed by the Mann -Whitney U nonparametric test. Mouse survival was analyzed using a Kaplan -Meier survival plot followed by a log -rank ( Mantel -Cox ) test to identify significant differences in survival between groups. Differences were considered statistically significant when the P value was < .05.
Results
In order to ensure that the secreted TIMP -1 encoded by TIMP-1pDNA was biologically active, an in vitro tumor invasion assay was performed on supernatant from NIH3T3 cells that had been transfected with TIMP-1pDNA. The supernatant from TIMP -1pDNA -transfected cells decreased
Cancer Gene Therapy To determine whether muscle cells can take up plasmid DNA and express the TIMP -1 gene efficiently, 50 g of pRc /CMV-lacZ encoding the -galactosidase gene was injected into the rectus femoris muscle of three mice. The animals were sacrificed, and the muscle was removed and stained for -galactosidase 72 hours after injection. As shown in Figure 1 , the muscle cells can indeed incorporate the plasmid and express the lacZ gene efficiently.
To ascertain whether TIMP -1pDNA injection could give rise to serum levels of human TIMP -1 and what injection frequency is required to maintain appreciable levels of human TIMP -1 protein in the serum, each of six mice was subjected to a single i.m. injection of 100 g of TIMP -1pDNA. Serum was collected every 2 -3 days for 9 days postinjection and analyzed by human TIMP-1 ELISA. As shown in Figure 2 , human TIMP -1 levels peaked in the serum 3 days after injection ( 120 pg /mL ) and were maintained at significant levels to day 9 ( 55 pg /mL ) -the final time point in the study. Mice injected with the control pDNA ( pRc /CMV ) were negative in the TIMP -1 ELISA. Therefore, we elected to inject TIMP -1pDNA twice per week so as to maintain high hTIMP -1 levels in the serum and thus maximize its antitumor metastasis potential.
To investigate the potential of TIMP -1 gene therapy for metastatic melanoma, three treatment modalities were used: TIMP -1 treatment alone ( 100 g of TIMP -1pDNA i.m. injection twice per week for 4 weeks, with treatment starting 3 days following tumor inoculation ), IL -2 treatment alone ( 1000 U of IL -2 intraperitoneal (i.p. ) injection, twice per week for 4 weeks), and combined TIMP -1 and IL -2 treatments. The mice were killed on day 30, and lung tumor nodules were counted. The average number of lung metastatic nodules was 97.83 ± 6.17 in the TIMP -1 group ( n =7 ), 115.52 ± 8.41 in the IL -2 group (n = 5), 64.00 ± 3.45 in the combined TIMP -1 and IL -2 group (n = 7), and 215± 10.32 in the control group (n =6 ), which received only vector DNA alone. More than 50% reduction in the number of lung metastatic nodules was observed both in the TIMP -1 and the IL -2 treatment groups as compared to the control group (Figs 3 and 4, P < .01 ). When combined TIMP-1 and IL -2 treatments were applied, the number of lung metastatic nodules was further reduced by 70% as compared to the control (P < .01), and 35% as compared to the TIMP -1 treatment alone ( P <.05 ). Although TIMP -1 treatment alone did not increase survival significantly (P >.05), mice treated with IL -2 and TIMP -1 together experienced a significant increase in survival as compared to the control group ( P <.01) or the group receiving TIMP -1 treatment alone Figure 1 X -gal staining of the rectus femoris muscle of C57BL / 6 mice following injection of plasmid pRc / CMV -lacZ. Fifty micrograms of pRc / CMV -lacZ was injected into the rectus femoris muscle of the hind leg ( A ). The same amount of pRc / CMV vector DNA was also injected as a control ( B ). The mice were killed on day 3 postinjection, and the muscle was removed and stained for -galactosidase, using a -gal staining kit from Invitrogen ( Carlsbad, CA ), according to the manufacturer's Figure 2 Serum hTIMP -1 levels in C57BL / 6 mice after a single i.m. injection of 100 g of TIMP -1pDNA. Serum was collected every 2 -3 days for 9 days after injection and analyzed by an ELISA specific for human TIMP -1. Each data point represents the mean hTIMP -1 serum level in six mice.
Cancer Gene Therapy TIMP-1 gene therapy of melanoma Y Shi et al ( P <.05 ) ( Fig 5) . The median survival of mice in the control ( n= 7), IL -2 alone (n = 6), TIMP -1 alone (n = 6), and TIMP -1 and IL -2 groups (n = 7) was 24, 28, 29, and 38 days, respectively. Several cytokines, including IL -2, IFN -, and IL -12, have been used in tumor immunotherapy. It is uncertain as to whether these cytokines can up -regulate TIMP-1 expression. Therefore, TIMP -1 expression was studied in NIH3T3 cells following 24-hour treatment with IL -2 as well as one of several other cytokines such as TGF -1, IL -12, IL -4, and IFN -. As shown in Figure 6 , all these cytokines can increase TIMP-1 expression. RNA loading in lane 6 was much lower than in lane 4 (control ). Densitometric analysis was performed and showed that TGF -expression (lane 6) was increased 2 -fold as Three days following tumor cell implant, mice were injected i.m. with 100 g of TIMP -1pDNA ( n = 6 ), control pDNA ( pRc / CMV ) ( n = 7 ), IL -2 alone ( n = 6 ), or a combination of 1000 U of IL -2 and 100 g of TIMP -1pDNA ( n = 7 ), twice a week for 4 weeks. Survival of the mice was monitored for 60 days. (lane 4 ) . Surprisingly, IL -2 and TGF -1 can also increase exogenous TIMP -1 expression ( Fig 6, lanes 2 and 3 ) . Given that exogenous TIMP-1 expression is under the control of human cytomegalovirus ( CMV ) promoter and enhancer, it is likely that IL-2 and TGF -1 are capable of enhancing CMV promoter and enhancer activities.
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Discussion
The data presented herein clearly demonstrate that experimental melanoma pulmonary metastasis in mice could be treated by distant i.m. delivery of plasmid encoding TIMP-1. The antimetastatic effect of TIMP -1 correlates with increased serum TIMP -1 levels after TIMP -1pDNA injection.
Overexpression of TIMPs by cancer cells, or by the surrounding host microenvironment, reduces the invasive and metastatic potential of tumor cells. 25 -27 Therefore, gene therapy by local or systemic overexpression of TIMPs may provide an opportunity to counter cancer cell invasion and metastases. Indeed, Brand et al 28 have demonstrated that overexpression of TIMP -2 in liver tissue by adenoviral transfer of the TIMP -2 gene can significantly reduce tumor cell metastasis to the liver following subsequent tumor cell challenge. Our method offers an alternative strategy to control tumor metastasis because the approach does not require local injection, and is therefore more suitable for the prevention of metastatic spread to distant sites.
Several investigators have conducted studies using recombinant TIMP -1 to treat tumor metastasis. 29, 30 Their results reveal that recombinant TIMP -1 is a potent inhibitor of the metalloproteinase activities of tumor cells and can also inhibit their metastatic potential. However, due to its short half -life in vivo, recombinant TIMP has been deemed unsuitable for pharmacologic application. 31 Instead, synthetic, low -molecular -weight MMP inhibitors ( BB -94, BB2516, BAY 12 -9566 ) have been employed for antitumor metastasis. These agents are currently in Phase I /II clinical trials to treat cancer patients and some undesirable systemic side effects have been reported. 31 -33 For example, BAY 12-9566, a synthetic MMP inhibitor with relative specificity against MMP -2, MMP -3, and MMP -9, has been tested in a Phase I pharmacological study. Oral dose of 800 mg, twice daily, resulted in biologically relevant plasma levels. The most common side effects were headache, nausea, vomiting, abnormalities in hepatic functions, and thrombocytopenia. 33 Alternatively, one might use TIMP-1 gene transfer as an adjuvant therapy for malignant tumors. Gene therapy using pDNA encoding a TIMP gene may offer some advantages over synthetic MMP inhibitors. The systemic side effects associated with synthetic MMP inhibitors may be reduced by the lower, but sustainable, serum levels of TIMP after i.m. injection, as well as a requirement for a less frequent dosing regimen (twice weekly versus daily).
Our data demonstrate that TIMP -1 and IL -2 combined treatment significantly reduces pulmonary metastasis and increases survival as compared to TIMP -1 treatment alone. This is probably due to IL -2 -induced up -regulation of both exogenous and endogenous TIMP -1 expression, as well as the ability of IL -2 boost host immune response against cancer cells through stimulation of T, B, and NK cells. Clearly, combined treatment with IL-2 and TIMP -1 has an additive effect against tumor metastasis. It is increasingly recognized that cytokines play important roles in regulating gene expression of MMPs as well as their inhibitors -TIMPs. Cytokine-dependent regulation of TIMP expression provides another mechanism for controlling the activity of MMPs. We have found that IL -2 and several other cytokines, such as TGF -1, IL-4, IL -12, and IFN -, could increase the number of TIMP-1 transcripts by at least 2 -to 3-fold in NIH3T3 cells. Several studies have reported that TIMP -1 expression can be dramatically up-regulated by IL -1, TNF -, and TGF -in other cell types. 34 -38 Cytokines such as IL-2, IFN -, and IL -12 have been used in tumor immunotherapy. 39 The demonstration of increased TIMP -1 expression by these cytokines provides further support for combined regimen in cancer management. 1 -3 ) or without TIMP -1pDNA ( lanes 4 -9 ) were treated with IL -2 ( 500 U / mL ), TGF -1 ( 20 ng / mL ), IL -12 ( 25 ng / mL ), IL -4 ( 100 U / mL ), or IFN -( 1000 U / mL ) for 24 hours. TIMP -1 expression was determined by Northern blot hybridization, using a full -length TIMP -1 cDNA probe and 20 g of total RNA extracted from NIH3T3 cells ( upper panel ). The endogenous TIMP -1 transcript is 0.9 kb in length, whereas the transfected one is 1.1 kb. RNA loading was monitored by ethidium bromide staining of RNA used in Northern blot analysis ( lower panel ).
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